CTCs were also marked by PDL1 to evaluate PDL1 status on cycle 1, day 1 (C1D1, baseline) in NSCLC patients receiving sequential treatment of THIO and cemiplimab as third-line and beyond treatment. The gene discussed is CD274; the disease is non-small cell lung carcinoma.